Quantitative EEG in schizophrenic patients before and during pharmacotherapy

Area of Science:

• Neuroscience
• Psychiatry
• Clinical Neurophysiology

Background:

• Schizophrenia is a complex mental disorder often treated with neuroleptic medications.
• Quantitative electroencephalography (qEEG) offers insights into brain activity patterns.

Purpose of the Study:

• To investigate changes in quantitative electroencephalography (qEEG) parameters in schizophrenia patients before and during neuroleptic therapy.
• To identify specific qEEG spectral activities affected by pharmacotherapy.

Main Methods:

• Electroencephalography (EEG) recordings were taken from 50 schizophrenia patients before and during neuroleptic treatment.
• Fast Fourier Transformation (FFT) analyzed amplitude values in delta, theta, alpha 1, alpha 2, beta 1, and beta 2 spectral bands.
• EEG data was analyzed across multiple brain regions (F3, F4, C3, C4, T3, T4, P3, P4, O1, O2).

Main Results:

• Neuroleptic pharmacotherapy led to a significant decrease in delta and beta 2 brainwave activities.
• Delta spectrum alterations were consistently observed across all patient subgroups, irrespective of the specific neuroleptic used.
• Changes in beta 2 activity were specifically noted in patients treated with haloperidol and fluphenazine.

Conclusions:

• Neuroleptic treatment demonstrably alters quantitative EEG parameters in schizophrenia patients.
• The observed decrease in delta activity appears to be a general effect of neuroleptic therapy in schizophrenia.
• Beta 2 activity changes may be more specific to certain neuroleptic medications, such as haloperidol and fluphenazine.